Off-label use of anlotinib in malignancies’ treatment: efficacy and management of adverse reactions
Pharmacological Reports, ISSN: 2299-5684, Vol: 77, Issue: 2, Page: 392-408
2025
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Mentions1
- News Mentions1
- 1
Most Recent News
Study Results from Jilin Provincial Cancer Hospital Broaden Understanding of Clinical Oncology (Off-label Use of Anlotinib In Malignancies' Treatment: Efficacy and Management of Adverse Reactions)
2025 FEB 27 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Data detailed on Clinical Oncology have been presented. According
Review Description
Anlotinib is a novel small-molecule multi-target tyrosine kinase inhibitor (TKIs) independently developed in China, it possesses the functions of inhibiting tumor angiogenesis and suppressing tumor growth. Anlotinib has achieved notable therapeutic effects in approved indications for advanced non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer, and medullary thyroid carcinoma. Additionally, with unanimous expert consensus, it has been used off-label in various other tumors, yielding favorable outcomes. This article reviews the efficacy and common adverse reactions, as well as their management, of off-label use of anlotinib in various malignant tumors.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85217628674&origin=inward; http://dx.doi.org/10.1007/s43440-025-00700-1; http://www.ncbi.nlm.nih.gov/pubmed/39899257; https://link.springer.com/10.1007/s43440-025-00700-1; https://dx.doi.org/10.1007/s43440-025-00700-1; https://link.springer.com/article/10.1007/s43440-025-00700-1
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know